
1000.0
100.0
10.0
1.0
0.1
Concentration (ng/mL)
0
6
12
18
24
30
36
42
48
Time (hr)
Males, first weekly dose
Females, first weekly dose
Males, third weekly dose
Females, third weekly dose

FIGURE 1


100.0
10.0
1.0
0.1
Concentration (ng/mL)
0
6
12
18
24
30
36
42
48
Time (hr)
Males, first weekly dose
Females, first weekly dose
Males, third weekly dose
Females, third weekly dose

FIGURE 2


Male Monkey 101
% Methylation
100
95
90
85
80
75
* p < 0.05
Pretest
D4
D11
D15
D22
Female Monkey 102
% Methylation
100
95
90
85
80
75
* p < 0.05
Pretest
D4
D8
D11
D15
D22

FIGURE 3


140%
120%
100%
80%
60%
40%
20%
0%
-20%
0
5
10
15
20
% change of total related substance with respect to T0
Time, hrs
100% DMSO
95/5 DMSO/WFI
90/10 DMSO/WFI
75/25 DMSO/WFI
50/50 DMSO/WFI

FIGURE 4


3.50
3.00
2.50
2.00
1.50
1.00
0.50
0.00
1 2 3 4 5 6 8 9 11 13 14 16 20 23 27 29 34 37
days
CTRL
SGI
CTLA-4 con
CTLA-4 subs
SGI+CTLA-4 con
SGI+CTLA-4 Subs
SGI-110
CTLA-4
concurrent
CTLA-4
subsequent

FIGURE 5


Tumor volume cm3
3,00
2,50
2,00
1,50
1,00
0,50
0,00
Vehicle qdx5x2 SQ at days 1-5; 21-25
SGI-110 3mg/kg qdx5x2 SQ at days 1-5, 21-25
anti-murine CTLA-4x2 at days 8, 11, 14; 28, 31, 34
SGI-110 3mg/kg qdx5x2 SQ (at days 1-5; 21-25) + anti-murine CTLA-4x2 (at days 8, 11, 14; 28, 31, 34)
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43
SGI-110
Anti-CTLA-4
SGI-110
Anti-CTLA-4

FIGURE 6